‘More Isn’t Always Better’ With Adjuvant Chemotherapy in Colon Cancer
Tammy Triglianos, DNP, ANP-BC, AOCNP, discusses optimal adjuvant treatment approaches for patients with stage III colon cancer.
PRO Analysis of PROSPECT Trial Reveals Distinct Toxicity Profiles With FOLFOX vs Chemoradiation in Rectal Cancer
FOLFOX was associated with lower rates or diarrhea and bowel dysfunction, but higher rates of fatigue, anxiety, nausea, and neuropathy, in data from the phase 2/3 PROSPECT trial.
Patients With Metastatic Breast Cancer Maintain Quality of Life With Oral Elacestrant
Patient-reported outcomes among patients who received elacestrant were consistent with other endocrine therapies.
Nivolumab Following Radical Surgery Extends Disease-Free Survival Rates in Bladder Cancer
Nivolumab bested placebo in improving disease-free survival rates in patients with muscle-invasive urothelial carcinoma and muscle-invasive bladder cancer.
Nurses Call for More Research on Nutrition Challenges for Patients With AML/MDS
Victoria R. Crowder, BSN, RN, and co-investigators, highlight existing gaps in the understanding of malnutrition risks facing patients with acute myeloid leukemia and myelodysplastic syndromes.
Immune Engager Therapies Improve Responses, PFS in RRMM After CAR T-Cell Therapy
Liso-Cel Elicits Rapid, Durable Responses in Relapsed/Refractory CLL/SLL
Adding Azoles May Not Impact Efficacy of Ruxolitinib in Acute GVHD Treatment
Ruxolitinib Plus Belumosudil Confers a 55% Response Rate in GVHD
2 Commerce Drive Cranbury, NJ 08512